Our data indicate dysregulation of adipokines and gastrointestinal hormones present after chronic treatment with aripiprazole which is considered metabolically neutral in the polyI:C model of schizophrenia. Furthermore aripiprazole decreased serum levels of pro-inflammatory cytokines. Leptin and GLP-1 serum levels were significantly reduced, while ghrelin level was elevated. Aripiprazole did not influence body weight but it induced alterations in neurohumoral regulations. adipokines, gastrointestinal hormones and cytokines levels. PolyI:C model was not associated with changes in other parameters i.e. Altered lipid profile in polyI:C model was observed and a trend towards different dynamics of weight gain in polyI:C rats was noted in the absence of significant antipsychotic treatment effect. Aripiprazole (5 mg/kg, dissolved tablets, ABILIFY ® ) was administered once daily via oral gavage for a month. For this study 20 polyI:C and 20 control adult male offspring were used, randomly divided into 2 groups per 10 animals for chronic aripiprazole treatment and vehicle.
Polyinosinic:polycytidylic acid (polyI:C) was administered subcutaneously at a dose of 8Â mg/kg in 10Â ml on gestational day 15 to female Wistar rats. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Horska, Katerina Ruda-Kucerova, Jana Drazanova, Eva Karpisek, Michal Demlova, Regina Kasparek, Tomas Kotolova, Hana Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats.
0 kommentar(er)
